An Open Label Phase II Trial to Evaluate the Safety of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa

Trial Profile

An Open Label Phase II Trial to Evaluate the Safety of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Oct 2017

At a glance

  • Drugs IFX 1 (Primary)
  • Indications Hidradenitis suppurativa
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors InflaRx
  • Most Recent Events

    • 13 Oct 2017 According to an an InflaRx media release, data was presented in september 2017 at the 16th European Meeting on Complement in Human Disease and the 26th Meeting of the European Academy of Dermatology and Venerology.
    • 15 Sep 2017 Status changed from active, no longer recruiting to completed.
    • 07 Sep 2017 According to an an InflaRx media release, the company will present the details from the trial results at the 16th European Meeting on Complement in Human Disease and the 26th Meeting of the European Academy of Dermatology and Venerology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top